Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study

Completed · Not applicable · Has a placebo group

Conditions studied: Hypertension

In brief

The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.

Key facts

Study ID

NCT00425945

Run by

Stanford University

People needed

130

Starts

2006-10-01

Expected to finish

2008-08-01

Last updated by the study team

2014-04-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) < 100 mmHg
• Body mass index (BMI) 25.0-34.9
• Triglycerides (TG) < 450 mg/dL
• Low Density Lipoprotein (LDL) < 200 mg/dL
• Fasting blood glucose (FBG) < 126 mg/dL

You may not qualify if…

• DBP > 95 mmHg
• LDL > 170 mg/dL
• TG > 300 mg/dL
• FBG > 110 mg/dL

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.